JP2015500885A - 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 - Google Patents

癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 Download PDF

Info

Publication number
JP2015500885A
JP2015500885A JP2014548917A JP2014548917A JP2015500885A JP 2015500885 A JP2015500885 A JP 2015500885A JP 2014548917 A JP2014548917 A JP 2014548917A JP 2014548917 A JP2014548917 A JP 2014548917A JP 2015500885 A JP2015500885 A JP 2015500885A
Authority
JP
Japan
Prior art keywords
formula
alkyl
cancer
administered
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014548917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500885A5 (enExample
Inventor
ハート，チャールズ
モン，ファンイン
サン，ジェシカ
Original Assignee
スレッショルド ファーマシューティカルズ，インコーポレイテッド
スレッショルド ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッショルド ファーマシューティカルズ，インコーポレイテッド, スレッショルド ファーマシューティカルズ，インコーポレイテッド filed Critical スレッショルド ファーマシューティカルズ，インコーポレイテッド
Publication of JP2015500885A publication Critical patent/JP2015500885A/ja
Publication of JP2015500885A5 publication Critical patent/JP2015500885A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014548917A 2011-12-22 2012-12-20 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 Pending JP2015500885A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579605P 2011-12-22 2011-12-22
US61/579,605 2011-12-22
US201261617576P 2012-03-29 2012-03-29
US61/617,576 2012-03-29
PCT/US2012/071074 WO2013096687A1 (en) 2011-12-22 2012-12-20 Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017182053A Division JP2017218459A (ja) 2011-12-22 2017-09-22 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与

Publications (2)

Publication Number Publication Date
JP2015500885A true JP2015500885A (ja) 2015-01-08
JP2015500885A5 JP2015500885A5 (enExample) 2016-02-18

Family

ID=48669508

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014548917A Pending JP2015500885A (ja) 2011-12-22 2012-12-20 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
JP2017182053A Withdrawn JP2017218459A (ja) 2011-12-22 2017-09-22 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017182053A Withdrawn JP2017218459A (ja) 2011-12-22 2017-09-22 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与

Country Status (4)

Country Link
US (1) US9254299B2 (enExample)
EP (1) EP2793882A4 (enExample)
JP (2) JP2015500885A (enExample)
WO (1) WO2013096687A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105792845A (zh) 2013-07-26 2016-07-20 施瑞修德制药公司 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
EP3313819A1 (en) * 2015-06-23 2018-05-02 Case Western Reserve University Compositions and methods for treating cancer
AU2018278336A1 (en) * 2017-06-01 2020-01-16 Crt Pioneer Fund Lp Biomarkers and patient selection strategies
CA3140123A1 (en) * 2019-05-14 2020-11-19 Sierra Oncology, Inc. Methods of treating cancer using chk1 inhibitors
CN118076359A (zh) 2021-08-27 2024-05-24 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548A (zh) 2021-08-27 2024-03-05 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
WO2023226959A1 (zh) * 2022-05-23 2023-11-30 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502743A (ja) * 2005-06-29 2009-01-29 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド ホスホルアミデートアルキル化剤プロドラッグ
JP2010514787A (ja) * 2006-12-26 2010-05-06 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の治療のためのフォスフォルアミデートアルキル化剤プロドラッグ

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306727A (en) 1993-04-30 1994-04-26 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US7914994B2 (en) 1998-12-24 2011-03-29 Cepheid Method for separating an analyte from a sample
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
US20030091574A1 (en) 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
HUE026218T2 (en) 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
DE10237931A1 (de) 2002-08-14 2004-02-26 Endress + Hauser Gmbh + Co. Kg Vorrichtung zur Überwachung eines vorbestimmten Füllstands eines Messmediums in einem Behälter
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
ES2309484T3 (es) * 2003-01-09 2008-12-16 Pfizer Inc. Derivados de diazepinoindol como inhibidores de quinasa.
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
KR101167335B1 (ko) 2003-10-31 2012-07-19 오클랜드 유니서비시즈 리미티드 니트로페닐 머스타드, 니트로페닐아지리딘 알코올 및 이에상응하는 포스페이트, 및 타겟화된 세포독성제로서의이들의 용도
US7432106B2 (en) 2004-03-24 2008-10-07 Applied Biosystems Inc. Liquid processing device including gas trap, and system and method
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
EP1743038A4 (en) 2004-05-04 2007-11-21 Bayer Healthcare MN / CA IX / CA9 AND KIDNEY CANCER PROGNOSIS
US20070117784A1 (en) 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
CA2624707A1 (en) 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Method for selectively depleting hypoxic cells
WO2008033041A1 (en) 2006-09-11 2008-03-20 Auckland Uniservices Limited Cancer treatment
US7807454B2 (en) 2006-10-18 2010-10-05 The Regents Of The University Of California Microfluidic magnetophoretic device and methods for using the same
US8216607B2 (en) * 2008-03-17 2012-07-10 Roger Williams Hospital Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer
JP5731372B2 (ja) 2008-04-10 2015-06-10 ヴァージニア コモンウェルス ユニバーシティ 癌治療用腫瘍低酸素の誘発
WO2009139915A2 (en) 2008-05-15 2009-11-19 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
US8501765B2 (en) * 2008-06-11 2013-08-06 Genentech, Inc. Diazacarbazoles and methods of use
JP5765634B2 (ja) 2008-10-21 2015-08-19 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
WO2010108091A2 (en) 2009-03-20 2010-09-23 Pbs Biotech, Inc. Automatable aseptic sample withdrawal system
CA2760932A1 (en) 2009-05-04 2010-11-11 Thierry Nivaggioli Mtor pathway inhibitors for treating ocular disorders
MX2012005163A (es) 2009-11-06 2012-11-22 Infinity Pharmaceuticals Inc Formulaciones orales de un inhibidor de la ruta de hedgehog.
MX2012014416A (es) 2010-06-28 2013-02-27 Threshold Pharmaceuticals Inc Tratamiento de cancer de sangre.
KR20130045341A (ko) 2010-07-12 2013-05-03 쓰레솔드 파마슈티컬스, 인코포레이티드 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여
US10357577B2 (en) 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
KR20140038390A (ko) 2011-04-01 2014-03-28 쓰레솔드 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
RU2013147744A (ru) 2011-04-15 2015-05-20 Тресхолд Фармасьютикалз, Инк. Дозированная лекарственная форма для перорального применения
JP5805989B2 (ja) 2011-04-26 2015-11-10 大塚電子株式会社 電気泳動移動度測定用セル並びにそれを用いた測定装置及び測定方法
EP2793899A4 (en) 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
JP2015511226A (ja) 2012-01-31 2015-04-16 スレッショルド ファーマシューティカルズ，インコーポレイテッド 低酸素活性化プロドラッグ療法のための予測バイオマーカー

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502743A (ja) * 2005-06-29 2009-01-29 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド ホスホルアミデートアルキル化剤プロドラッグ
JP2010514787A (ja) * 2006-12-26 2010-05-06 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の治療のためのフォスフォルアミデートアルキル化剤プロドラッグ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HU, J. ET AL.: ""Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug"", BLOOD, vol. 116, no. 9, JPN6016036808, 2 September 2010 (2010-09-02), pages 1524 - 1527, ISSN: 0003406235 *
MA, C.X. ET AL.: ""Death by releaseing the breaks: CHK1 inhibitors as cancer therapeutics"", TRENDS MOL. MED., vol. 17, no. 2, JPN6016036806, February 2011 (2011-02-01), pages 88 - 96, ISSN: 0003406234 *
ZABLUDOFF, S.D. ET AL.: ""AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targ", MOL. CANCER THER., vol. 7, no. 9, JPN6016036804, September 2008 (2008-09-01), pages 2955 - 2966, ISSN: 0003406233 *

Also Published As

Publication number Publication date
EP2793882A1 (en) 2014-10-29
US9254299B2 (en) 2016-02-09
JP2017218459A (ja) 2017-12-14
US20150005263A1 (en) 2015-01-01
EP2793882A4 (en) 2015-04-29
WO2013096687A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
JP2017218459A (ja) 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
US20250295869A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
JP6904640B2 (ja) 癌の処置
JP7194022B2 (ja) Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
CN103458896B (zh) 用于治疗癌症的方法
JP2021535146A (ja) Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法
US20150005262A1 (en) Hypoxia activated prodrugs and mtor inhibitors for treating cancer
JP2013533257A (ja) 血液癌の治療法
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
CA2459822C (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
TWI649082B (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
HK1254083B (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
WO2025078334A1 (en) Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia
AU2011279391A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170523